case ID	acute/sustained	daily dosage	total dosage	dosage value	dosage units	dosage times per day	dosage duration	dosage comment	intervention class	intervention	dose dependence	sample group size	prophylactic / therapeutic	outcome	outcome direction	measure description	outcome group size	author conclusion	conclusion method	References	NCT Number	Title	Gender	Age Groups	Age Description	Phases	URL	intervention:Specific	intervention:Variation	outcome count	result
NCT02626104-2	sustained								control	100mgofplacebo-maltodextrintwiceadayorallyforthewholeperiodofantibiotictherapy.	no	78	prophylactic	Occurence of antibiotic-associated diarrhoea. [ Time Frame: Up to 24 days after initiation of antibiotic treatment. ]	positive	participants	7			https://www.embase.com/a/#/search/results?subaction=viewrecord&rid=1&page=1&id=L622343677	NCT02626104	Bovine Lactoferrin and Antibiotic-associated Diarrhoea.	all	child,adult	1 Year to 18 Years Â (Child, Adult)	phase2	https://ClinicalTrials.gov/show/NCT02626104			71.0	0.9102564102564102
NCT00958308-1	sustained			1	capsule			50 billion CFU	probiotic	bio-k+cl-1285,onecapsule+onecapsuleplacebo	yes	85	prophylactic	CDAD occurrence	positive	participants	8			https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx	NCT00958308	Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection	all	adult,olderadult	50 Years to 70 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00958308		Lactobacillus acidophilus	77.0	0.9058823529411765
NCT00958308-3	sustained			2	capsule			50 billion CFU	probiotic	bio-k+cl-1285,twocapsules	yes	86	prophylactic	CDAD occurrence	positive	participants	1			https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx	NCT00958308	Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection	all	adult,olderadult	50 Years to 70 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00958308		Lactobacillus acidophilus	85.0	0.9883720930232558
NCT02626104-1	sustained	200		100	mg	bid		for antiobiotic duration	other	bovinelactoferrin	no	78	prophylactic	Occurence of antibiotic-associated diarrhoea. [ Time Frame: Up to 24 days after initiation of antibiotic treatment. ]	positive	participants	16	inferior		https://www.embase.com/a/#/search/results?subaction=viewrecord&rid=1&page=1&id=L622343677	NCT02626104	Bovine Lactoferrin and Antibiotic-associated Diarrhoea.	all	child,adult	1 Year to 18 Years Â (Child, Adult)	phase2	https://ClinicalTrials.gov/show/NCT02626104			62.0	0.7948717948717948
NCT01983683-1	acute	500	5000	250	mg	bid	10		antibiotic	cadazolid	no	290	therapeutic	Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population	positive	percentageofparticipants	81 (76.1 to 85.1)   	Non-Inferiority	Wilson's score method	x	NCT01983683	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01983683	Cadazolid		234.9	0.8068965517241379
NCT01983683-3	sustained	500	5000	250	mg	bid	10		antibiotic	cadazolid	no	290	therapeutic	"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT)."	positive	percentageofparticipants	63.4 (57.8 to 68.8)	Superiority	Wilson's score method	x	NCT01983683	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01983683	Cadazolid		183.86	0.6310344827586207
NCT01987895-1	acute	500	5000	250	mg	bid	10		antibiotic	cadazolid	no	302	therapeutic	Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population	positive	percentageofparticipants	83.8 (79.2 to 87.5) 	Non-Inferiority	Wilson's score method	x	NCT01987895	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01987895	Cadazolid		253.076	0.8377483443708609
NCT01987895-3	sustained	500	5000	250	mg	bid	10		antibiotic	cadazolid	no	302	therapeutic	"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT)."	positive	percentageofparticipants	65.6 (60.0 to 70.7)	Superiority	Wilson's score method	x	NCT01987895	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01987895	Cadazolid		198.11199999999997	0.6556291390728477
NCT01222702-1	acute	500	5000	250	mg	bid	10		antibiotic	cadazolid	yes	17	therapeutic	Modified clinical cure rate	positive	participants	16			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		16.0	0.9411764705882353
NCT01222702-4	acute	1000	10000	500	mg	bid	10		antibiotic	cadazolid	yes	20	therapeutic	Modified clinical cure rate	positive	participants	18			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		18.0	0.9
NCT01222702-7	acute	2000	20000	1000	mg	bid	10		antibiotic	cadazolid	yes	19	therapeutic	Modified clinical cure rate	positive	participants	16			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		16.0	0.8421052631578947
NCT01222702-13	sustained	500	5000	250	mg	bid	10		antibiotic	cadazolid	yes	17	therapeutic	Modified sustained clinical response rate	positive	participants	13			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		13.0	0.7647058823529411
NCT01222702-16	sustained	1000	10000	500	mg	bid	10		antibiotic	cadazolid	yes	20	therapeutic	Modified sustained clinical response rate	positive	participants	14			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		14.0	0.7
NCT01222702-19	sustained	2000	20000	1000	mg	bid	10		antibiotic	cadazolid	yes	18	therapeutic	Modified sustained clinical response rate	positive	participants	10			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	Cadazolid		10.0	0.5555555555555556
NCT01085591-1	acute	250	2500	125	mg	bid	10		antibiotic	cb-183,315	yes	66	therapeutic	Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment	positive	participants	61		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	CB-183,315;surotomycin		61.0	0.9242424242424242
NCT01085591-3	acute	500	5000	250	mg	bid	10		antibiotic	cb-183,315	yes	67	therapeutic	Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment	positive	participants	58		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	CB-183,315;surotomycin		58.0	0.8656716417910447
NCT01085591-7	sustained	250	2500	125	mg	bid	10		antibiotic	cb-183,315	yes	61	therapeutic	Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period	positive	participants	17		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	CB-183,315;surotomycin		44.0	0.7213114754098361
NCT01085591-10	sustained	500	5000	250	mg	bid	10		antibiotic	cb-183,315	yes	58	therapeutic	Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period	positive	participants	10		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	CB-183,315;surotomycin		48.0	0.8275862068965517
NCT02254967-1	acute	400	5600	200	mg	bid	5	1 day gap + 200 mg QD for 18 days	antibiotic	extended-pulsedfidaxomicin	no	177	therapeutic	clinical reponse 2 days after end of treatment	positive	participants	138		Cochran-Mantel-Haenszel	https://doi.org/10.1016/s1473-3099(17)30751-x	NCT02254967	A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population	all	adult,olderadult	60 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02254967		fidaxomicin;Tiacumicins B	138.0	0.7796610169491526
NCT02254967-3	sustained	400	5600	200	mg	bid	5	1 day gap + 200 mg QD for 18 days	antibiotic	extended-pulsedfidaxomicin	no	177	therapeutic	sustained clinical cure 30 days after end of treatment	positive	participants	124	Superiority	Cochran-Mantel-Haenszel	https://doi.org/10.1016/s1473-3099(17)30751-x	NCT02254967	A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population	all	adult,olderadult	60 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02254967		fidaxomicin;Tiacumicins B	124.0	0.7005649717514124
NCT01704937-1	sustained								fmt	"fecalmicrobiotatransplant(""stooltransplant"")fromhealthy,unrelateddonorviacolonoscopy"	no	10	therapeutic	Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile	positive	participants	8			https://pubmed.ncbi.nlm.nih.gov/24762631/	NCT01704937	Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum	all	child,adult,olderadult	7 Years to 90 Years Â (Child, Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT01704937		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	8.0	0.8
NCT01704937-2	sustained								fmt	"fecalmicrobiotatransplant(""stooltransplant"")fromhealthy,unrelateddonorviangt"	no	10	therapeutic	Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile	positive	participants	6			https://pubmed.ncbi.nlm.nih.gov/24762631/	NCT01704937	Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum	all	child,adult,olderadult	7 Years to 90 Years Â (Child, Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT01704937		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	6.0	0.6
NCT02465463-1	sustained	250	250	250	ml	qd	1		fmt	fecalmicrobiotatransplant(fmt):250mlofdonorstoolwillbeinfusedintothecolonbyflexiblesigmoidoscopy	no	4	therapeutic	Clinical Remission Rates [ Time Frame: Post-Intervention (Week 12) ]	positive	participants	3			x	NCT02465463	Early FMT for C.Difficile	all	adult,olderadult	18 Years to 79 Years Â (Adult, Older Adult)	phase1|phase2	https://ClinicalTrials.gov/show/NCT02465463		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	3.0	0.75
NCT02254811-2	sustained								fmt	fecalmicrobiotatransplantdeliveredbycolonoscopy	no	59	therapeutic	Proportion of patients without recurrent CDI [ Time Frame: 12 weeks after treatment ]	positive	participants	50	non-inferiority	(difference, 0%; 1-sided 95% CI, -6.1% to infinity; P < .001),	https://pubmed.ncbi.nlm.nih.gov/29183074/	NCT02254811	FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2|phase3	https://ClinicalTrials.gov/show/NCT02254811		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	50.0	0.847457627118644
NCT02254811-1	sustained								fmt	fecalmicrobiotatransplantisdeliveredbyoralcapsules	no	57	therapeutic	Proportion of patients without recurrent CDI [ Time Frame: 12 weeks after treatment ]	positive	participants	51	non-inferiority	(difference, 0%; 1-sided 95% CI, -6.1% to infinity; P < .001),	https://pubmed.ncbi.nlm.nih.gov/29183074/	NCT02254811	FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2|phase3	https://ClinicalTrials.gov/show/NCT02254811		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	51.0	0.8947368421052632
NCT02148601-1	sustained								fmt	fecalmicrobiotatransplantation	no	20	therapeutic	Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ]	positive	participants	18	superior	(P < 0.0001).	https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144	NCT02148601	Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection	all	adult,olderadult	18 Years to 95 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02148601		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	18.0	0.9
NCT03106844-1	sustained								fmt	fecalmicrobiotatransplantation	no	49	therapeutic	Number of Participants With FMT Failure [ Time Frame: 8 weeks ] - recurrence of c diff	positive	participants	4			x	NCT03106844	The ICON Study: Outcomes After FMT for Patients With IBD and CDI	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase1|phase2	https://ClinicalTrials.gov/show/NCT03106844		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	45.0	0.9183673469387755
NCT01087892-1	acute	200	1400	100	g	bid	7	7 days + duration of antibiotics	probiotic	fermentedmilkpreparationofl.caseidn114001(108colony-formingunits(cfu)/ml)aswellastworegularyoghurtculturesl.delbrueckiisubspeciesbulgaricusands.thermophilus(106cfu/ml)	no	549	prophylactic	incidence and duration of Clostridium difficile toxin [ Time Frame: regular intervals for 28 days from entry to trial ]	positive	participants	8	not superior		https://www.journalofhospitalinfection.com/article/S0195-6701(20)30042-6/fulltext	NCT01087892	Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection	all	adult,olderadult	55 Years and older Â (Adult, Older Adult)	notapplicable	https://ClinicalTrials.gov/show/NCT01087892			541.0	0.9854280510018215
NCT01591863-1	acute	400	4000	200	mg	bid	10	different dosages by age, only recorded 6 year and older dosage	antibiotic	fidaxomicin	no	38	therapeutic	Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10)	positive	percentageofparticipants	92.1 (83.5 to 100)			x	NCT01591863	Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child,adult	6 Months to 18 Years Â (Child, Adult)	phase2	https://ClinicalTrials.gov/show/NCT01591863	fidaxomicin;Tiacumicins B		34.998	0.8947368421052632
NCT01591863-2	sustained	400	4000	200	mg	bid	10	different dosages by age, only recorded 6 year and older dosage	antibiotic	fidaxomicin	no	38	therapeutic	Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28)	positive	percentageofparticipants	65.8 (50.7 to 80.9)			x	NCT01591863	Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child,adult	6 Months to 18 Years Â (Child, Adult)	phase2	https://ClinicalTrials.gov/show/NCT01591863	fidaxomicin;Tiacumicins B		25.004	0.6578947368421053
NCT02179658-1	acute	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	104	therapeutic	Clinical cure at end of treatment	positive	participants	87			https://pubmed.ncbi.nlm.nih.gov/29934056/	NCT02179658	A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	adult,olderadult	20 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02179658	fidaxomicin;Tiacumicins B		87.0	0.8365384615384616
NCT02179658-3	sustained	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	104	therapeutic	Global cure at end of treatment	positive	participants	70	not non-inferior	with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%	https://pubmed.ncbi.nlm.nih.gov/29934056/	NCT02179658	A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	adult,olderadult	20 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02179658	fidaxomicin;Tiacumicins B		70.0	0.6730769230769231
NCT02743234-3	acute	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	24	therapeutic	Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]	positive	participants	8		chi^2 and Kruskal-Wallis anova	https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234	fidaxomicin;Tiacumicins B		8.0	0.3333333333333333
NCT02743234-9	sustained	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	24	therapeutic	initially cured, then relapsed	positive	participants	11			https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234	fidaxomicin;Tiacumicins B		13.0	0.5416666666666666
NCT02784002-1	sustained	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	13	therapeutic	Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]	positive	participants	6	equivalence	estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7	https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841	NCT02784002	A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02784002	fidaxomicin;Tiacumicins B		6.0	0.46153846153846156
NCT02218372-1	acute	400	4000	200	mg	bid	10	staggered age dependent dose, recorded >6 years dosage	antibiotic	fidaxomicin	no	98	therapeutic	Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days	positive	percentageofparticipants	77.6 (68.0 to 85.4)		Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.	x	NCT02218372	A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child	up to 17 Years Â (Child)	phase3	https://ClinicalTrials.gov/show/NCT02218372	fidaxomicin;Tiacumicins B		76.04799999999999	0.7755102040816326
NCT02218372-3	sustained	400	4000	200	mg	bid	10	staggered age dependent dose, recorded >6 years dosage	antibiotic	fidaxomicin	no	76	therapeutic	Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days	positive	percentageofparticipants	94.7 (87.1 to 98.5)		Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.	x	NCT02218372	A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child	up to 17 Years Â (Child)	phase3	https://ClinicalTrials.gov/show/NCT02218372	fidaxomicin;Tiacumicins B		71.972	0.9342105263157895
NCT01691248-1	sustained	200	16000	200	mg	qd	40	up to 40 days	antibiotic	fidaxomicin	no	301	prophylactic	Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. [ Time Frame: Up to 30 days post-treatment ]	positive	percentageofparticipants	28.6 (23.5 to 33.7)	not superior	1-sided Wald test for a difference in proportions using an unpooled estimate of variance.	x	NCT01691248	Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01691248	fidaxomicin;Tiacumicins B		214.914	0.7109634551495017
NCT02437591-1	acute	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	25	therapeutic	CDI clinical response [ Time Frame: Day 12 ]	positive	participants	20			https://astellasclinicalstudyresults.com/study.aspx?ID=227	NCT02437591	Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02437591	fidaxomicin;Tiacumicins B		20.0	0.8
NCT00314951-2	acute	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	289	therapeutic	Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ]	positive	percentageofparticipants	88.2 (84.0 to 91.5)	non-inferior	H0: C(fidaxomicin) - C(Vancomycin) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.	x	NCT00314951	Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00314951	fidaxomicin;Tiacumicins B		254.898	0.8788927335640139
NCT00314951-4	sustained	400	4000	200	mg	bid	10		antibiotic	fidaxomicin	no	255	therapeutic	Recurrence [ Time Frame: Study days 11-40 ]	positive	percentageofparticipants	15.7	superior	Chi-squared	x	NCT00314951	Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00314951	fidaxomicin;Tiacumicins B		214.965	0.8392156862745098
NCT01818141-1	acute	400	4000	200	mg	bid	10	200 mg BID for 10 days	antibiotic	fidaxomicin200mgbymouthevery12hoursfor10days	no	12	therapeutic	C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool	positive	participants	11			x	NCT01818141	Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01818141	fidaxomicin;Tiacumicins B		11.0	0.9166666666666666
NCT01818141-3	acute	400	4000	200	mg	bid	10	200mg BID for 10 days	antibiotic	fidaxomicin200mgbymouthevery12hoursfor10days	no	7	therapeutic	C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool	positive	participants	4			x	NCT01818141	Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01818141	fidaxomicin;Tiacumicins B		4.0	0.5714285714285714
NCT02743234-1	acute								fmt	fmtfollowing4-10daysvancomycin125mgx4daily	no	24	therapeutic	Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]	positive	participants	17	superior	chi^2 and Kruskal-Wallis anova	https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	17.0	0.7083333333333334
NCT02743234-7	sustained								fmt	fmtfollowing4-10daysvancomycin125mgx4daily	no	24	therapeutic	initially cured, then relapsed	positive	participants	2			https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	22.0	0.9166666666666666
NCT01398969-1	sustained								fmt	freshhumanbiotherapy	no	111	therapeutic	To determine the cure rate without recurrence of CDI at 13 weeks from the last HBT. [ Time Frame: 13 Weeks post HBT ]	positive	participants	78		(difference, 4.7% [95% CI, -5.2% to ∞]; P < .001 for noninferiority)	https://pubmed.ncbi.nlm.nih.gov/26757463/	NCT01398969	Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01398969		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	78.0	0.7027027027027027
NCT01398969-2	sustained								fmt	frozen-and-thawedhumanbiotherapy	no	108	therapeutic	To determine the cure rate without recurrence of CDI at 13 weeks from the last HBT. [ Time Frame: 13 Weeks post HBT ]	positive	participants	81	non-inferior		https://pubmed.ncbi.nlm.nih.gov/26757463/	NCT01398969	Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01398969		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	81.0	0.75
NCT02951702-2	sustained								control	historicalcontrol	no	34	prophylactic	Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ]	positive	participants	2			x	NCT02951702	Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics	all	olderadult	65 Years and older Â (Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02951702			32.0	0.9411764705882353
NCT02865616-1	sustained							staggered dosing depending on outcome	probiotic	met-2	no	19	therapeutic	absence of C difficile infection recurrence at day 40	positive	participants	18			https://pubmed.ncbi.nlm.nih.gov/33631102/	NCT02865616	MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT02865616			18.0	0.9473684210526315
NCT00182429-1	sustained	1500	15000	500	mg	tid	10		antibiotic	metronidazole	no	20	therapeutic	Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).	positive	participants	4			https://academic.oup.com/cid/article/43/5/547/503445	NCT00182429	Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment	all	child,adult,olderadult	14 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00182429	metronidazole		4.0	0.2
NCT00196794-3	acute	1500	15000	375	mg	qid	10		antibiotic	metronidazole	no	135	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	73.3			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	metronidazole		98.955	0.725925925925926
NCT00196794-9	sustained	1500	15000	375	mg	qid	10		antibiotic	metronidazole	no	106	therapeutic	Recurrence rate	positive	percentageofparticipants	18.9			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	metronidazole		85.96600000000001	0.8018867924528302
NCT00106509-3	acute	1500	15000	375	mg	qid	10		antibiotic	metronidazole	no	143	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	72			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	metronidazole		102.96	0.7132867132867133
NCT00106509-9	sustained	1500	15000	375	mg	qid	10		antibiotic	metronidazole	no	107	therapeutic	Recurrence rate	positive	percentageofparticipants	27.1			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	metronidazole		78.003	0.7289719626168224
NCT01241552-1	sustained	10	10	10	mg/kg	qd	1		antibody	mk-3415+standardofcare	no	232	therapeutic	Percentage of Participants With CDI Recurrence	positive	percentageofparticipants	25.9		One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).	x	NCT01241552	A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01241552		CDA1	171.912	0.7370689655172413
NCT01513239-1	sustained	10	10	10	mg/kg	qd	1		antibody	mk-6072+standardofcare	no	390	therapeutic	Percentage of Participants With CDI Recurrence	positive	percentageofparticipants	14.9	Superior	One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)	x	NCT01513239	A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01513239		MDX1388	331.89	0.8487179487179487
NCT01241552-6	sustained	10	10	10	mg/kg	qd	1		antibody	mk-6072+standardofcare	no	386	therapeutic	Percentage of Participants With CDI Recurrence	positive	percentageofparticipants	17.4	superior	One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).	x	NCT01241552	A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01241552		MDX1388	318.836	0.8238341968911918
NCT00304356-1	sustained	1000		500	mg	bid			other	nitazoxanide	no	27	therapeutic	Nitazoxanide [ Time Frame: 30 days ] - stopping of diarrhea	positive	participants	27			x	NCT00304356	Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00304356	Nitazoxanide		27.0	1.0
NCT02465463-2	sustained								control	nointervention	no	4	therapeutic	Clinical Remission Rates [ Time Frame: Post-Intervention (Week 12) ]	positive	participants	2			x	NCT02465463	Early FMT for C.Difficile	all	adult,olderadult	18 Years to 79 Years Â (Adult, Older Adult)	phase1|phase2	https://ClinicalTrials.gov/show/NCT02465463			2.0	0.5
NCT00350298-4	sustained								control	normalsaline	no	99	therapeutic	Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ]	positive	participants	25			x	NCT00350298	Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00350298			74.0	0.7474747474747475
NCT00097422-1	acute	100	1000	50	mg	bid	10	50 mg	antibiotic	opt-80	yes	14	therapeutic	Relief of symptoms of CDAD	positive	participants	10			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		10.0	0.7142857142857143
NCT00097422-3	acute	200	2000	100	mg	bid	10	100 mg	antibiotic	opt-80	yes	15	therapeutic	Relief of symptoms of CDAD	positive	participants	12			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		12.0	0.8
NCT00097422-5	acute	400	4000	200	mg	bid	10	200 mg	antibiotic	opt-80	yes	16	therapeutic	Relief of symptoms of CDAD	positive	participants	15			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		15.0	0.9375
NCT00097422-7	sustained	100	1000	50	mg	bid	10	50 mg	antibiotic	opt-80	yes	10	therapeutic	Recurrence Rate.	positive	participants	1			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		9.0	0.9
NCT00097422-9	sustained	200	2000	100	mg	bid	10	100 mg	antibiotic	opt-80	yes	12	therapeutic	Recurrence Rate.	positive	participants	0			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		12.0	1.0
NCT00097422-11	sustained	400	4000	200	mg	bid	10	200 mg	antibiotic	opt-80	yes	15	therapeutic	Recurrence Rate.	positive	participants	1			https://pubmed.ncbi.nlm.nih.gov/18955525/	NCT00097422	OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT00097422	fidaxomicin;Tiacumicins B		14.0	0.9333333333333333
NCT03110133-1	sustained								probiotic	oralfull-spectrummicrobiotatm(cp101)	no	102	therapeutic	Proportion of patients with no recurrence of symptomatic, laboratory confirmed C. difficile infection [ Time Frame: Week 8 ]	positive	participants	76	superior	relative risk reduction (RRR) 21%;74.5%(76/102) vs. 61.5%(59/96),p¼0.0488	https://journals.sagepub.com/doi/pdf/10.1177/2050640620968709	NCT03110133	Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT03110133			76.0	0.7450980392156863
NCT01085591-6	acute	500	5000	125	mg	qid	10		antibiotic	oralvancomycin	yes	66	therapeutic	Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment	positive	participants	59		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	vancomycin		59.0	0.8939393939393939
NCT01085591-11	sustained	500	5000	125	mg	qid	10		antibiotic	oralvancomycin	yes	59	therapeutic	Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period	positive	participants	21		1	x	NCT01085591	Study of CB-183,315 in Participants With Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01085591	vancomycin		38.0	0.6440677966101694
NCT02951702-1	sustained	125		125	mg	qd		unspecified duration	antibiotic	oralvancomycin125mgdaily	no	17	prophylactic	Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ]	positive	participants	0			x	NCT02951702	Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics	all	olderadult	65 Years and older Â (Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02951702	vancomycin		17.0	1.0
NCT01914731-1	acute								fmt	oral,capsulized,frozenfecalmicrobiotatransplantation	no	20	therapeutic	clinical resolution of diarrhea after the first administration of FMT	positive	participants	14	success	95% CI	https://doi.org/10.1001/jama.2014.13875	NCT01914731	Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum	all	child,adult,olderadult	7 Years to 90 Years Â (Child, Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT01914731		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	14.0	0.7
NCT01914731-2	acute								fmt	oral,capsulized,frozenfecalmicrobiotatransplantation	no	6	therapeutic	resolution of diarrhea after the second treatment	positive	participants	5	success	95% CI	https://doi.org/10.1001/jama.2014.13875	NCT01914731	Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum	all	child,adult,olderadult	7 Years to 90 Years Â (Child, Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT01914731		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	5.0	0.8333333333333334
NCT01914731-3	sustained								fmt	oral,capsulized,frozenfecalmicrobiotatransplantation	no	20	therapeutic	rate of diarrhea resolution at 8-weeks	positive	participants	19	success	95% CI	https://doi.org/10.1001/jama.2014.13875	NCT01914731	Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum	all	child,adult,olderadult	7 Years to 90 Years Â (Child, Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT01914731		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	19.0	0.95
NCT00468728-2	acute	400	4000	200	mg	bid	10		antibiotic	par-101/opt-80	no	253	therapeutic	Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ]	positive	percentageofparticipants	87.7 (83.1 to 91.2)	non-inferior	H0: C(OPT-80) - C(VAN) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.	x	NCT00468728	PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00468728	fidaxomicin;Tiacumicins B		221.88100000000003	0.8735177865612648
NCT00468728-4	sustained	400	4000	200	mg	bid	10		antibiotic	par-101/opt-80	no	222	therapeutic	Recurrence [ Time Frame: Study days 11-40 ]	positive	percentageofparticipants	12.6	superior	Chi-squared	x	NCT00468728	PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00468728	fidaxomicin;Tiacumicins B		194.028	0.8738738738738738
NCT02437487-2	acute								control	placebo	no	30	therapeutic	Number of Subjects With CDI Recurrence (8 weeks after)	positive	participants	16			https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059	NCT02437487	SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02437487			14.0	0.4666666666666667
NCT02437487-4	sustained								control	placebo	no	30	therapeutic	Number of Subjects With CDI Recurrence (8 weeks after)	positive	participants	16			https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059	NCT02437487	SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02437487			14.0	0.4666666666666667
NCT01259726-1	sustained								control	placebo	yes	43	therapeutic	Number of Participants With Clostridium Difficile Infection (CDI) Recurrence	positive	participants	13			x	NCT01259726	Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01259726			30.0	0.6976744186046512
NCT02299570-5	sustained								control	placebo	yes	44	therapeutic	The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).	positive	participants	19			x	NCT02299570	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02299570			19.0	0.4318181818181818
NCT01691248-2	sustained								control	placebo	no	209	prophylactic	Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. [ Time Frame: Up to 30 days post-treatment ]	positive	percentageofparticipants	30.8 (25.5 to 36.0)		1-sided Wald test for a difference in proportions using an unpooled estimate of variance.	x	NCT01691248	Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01691248			144.628	0.6889952153110048
NCT00958308-5	sustained								control	placebo	yes	84	prophylactic	CDAD occurrence	positive	participants	20			https://journals.lww.com/ajg/Abstract/2010/07000/Dose_Response_Efficacy_of_a_Proprietary_Probiotic.30.aspx	NCT00958308	Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection	all	adult,olderadult	50 Years to 70 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00958308			64.0	0.7619047619047619
NCT01680874-4	sustained								control	placebo	no	15	therapeutic	Recurrence of CDI [ Time Frame: 8 weeks ]	positive	participants	1			https://pubmed.ncbi.nlm.nih.gov/28961980/	NCT01680874	Probiotics for Clostridium Difficile Infection in Older Adults	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01680874			14.0	0.9333333333333333
NCT01087892-2	acute								control	placebo	no	577	prophylactic	incidence and duration of Clostridium difficile toxin [ Time Frame: regular intervals for 28 days from entry to trial ]	positive	participants	11			https://www.journalofhospitalinfection.com/article/S0195-6701(20)30042-6/fulltext	NCT01087892	Probiotics in Preventing Antibiotic Associated Diarrhoea Including Clostridium Difficile Infection	all	adult,olderadult	55 Years and older Â (Adult, Older Adult)	notapplicable	https://ClinicalTrials.gov/show/NCT01087892			566.0	0.9809358752166378
NCT03110133-2	sustained								control	placebo	no	96	therapeutic	Proportion of patients with no recurrence of symptomatic, laboratory confirmed C. difficile infection [ Time Frame: Week 8 ]	positive	participants	59			https://journals.sagepub.com/doi/pdf/10.1177/2050640620968709	NCT03110133	Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT03110133			59.0	0.6145833333333334
NCT01295918-2	sustained								control	placebo	no	48	prophylactic	To assess if the probiotic L. reuteri is effective in preventing AAD in children [ Time Frame: 2 years ]	positive	participants	47		The incidence of diarrhoea (defined as at least 3 loose or watery stools per day in a 48-hour period that occurred during or up to 21 days after cessation of antibiotic treatment) was unexpectedly low in both groups - L. reuteri (n=1) versus placebo (n=1): 2,04 vs. 2,1 per 100 (p>0,05, risk ratio 1,02, 95% CI 0,7-1,4).	http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p895-900.html	NCT01295918	Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children	all	child,adult	3 Years to 18 Years Â (Child, Adult)	phase3	https://ClinicalTrials.gov/show/NCT01295918			47.0	0.9791666666666666
NCT01670149-2	sustained								control	placebo	no	61	prophylactic	Difference in % relapse between Rifaximin and placebo at 12 weeks [ Time Frame: 12 weeks ]	positive	participants	18			https://gut.bmj.com/content/66/Suppl_2/A150.1	NCT01670149	Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01670149			43.0	0.7049180327868853
NCT00973908-1	acute								control	placebo	no	117	prophylactic	Development of Clostridium difficile associated diarrhoea [ Time Frame: 28 days post last antibiotic dose ]	positive	participants	0			https://pubmed.ncbi.nlm.nih.gov/23618760/	NCT00973908	Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2|phase3	https://ClinicalTrials.gov/show/NCT00973908			117.0	1.0
NCT02563106-2	sustained								control	placebo	no	206	prophylactic	Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up.	positive	participants	7			x	NCT02563106	A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI	all	adult,olderadult	50 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02563106			199.0	0.9660194174757282
NCT01513239-6	sustained								control	placebo+standardofcare	no	378	therapeutic	Percentage of Participants With CDI Recurrence	positive	percentageofparticipants	25.7			x	NCT01513239	A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01513239		vancomycin;vancomycin + metronidazole;metronidazole	280.854	0.7407407407407407
NCT01241552-12	sustained								antibiotic	placebo+standardofcare	no	395	therapeutic	Percentage of Participants With CDI Recurrence	positive	percentageofparticipants	27.6		One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).	x	NCT01241552	A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01241552		vancomycin;vancomycin + metronidazole;metronidazole	285.98	0.7215189873417721
NCT01680874-3	sustained			1	capsule	qd	28		probiotic	probioticcombinationwhichwillconsistofequalamountsoflactobacillusacidophilusncfm®(atcc700396),lactobacillusparacaseilpc-37(atccsd5275),bifidobacteriumlactisbi-07(atccsc5220),andbifidobacteriumlactisbl-04(atccsd5219)	no	16	therapeutic	Recurrence of CDI [ Time Frame: 8 weeks ]	positive	participants	1			https://pubmed.ncbi.nlm.nih.gov/28961980/	NCT01680874	Probiotics for Clostridium Difficile Infection in Older Adults	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01680874		consortium of probiotics including five Lactobacilli strains and two Bifidobacterium strains	15.0	0.9375
NCT00973908-2	acute	2	14	1	sachet	bid	7	7 days + duration of antibiotics	probiotic	probioticformulationvsl#3	no	112	prophylactic	Development of Clostridium difficile associated diarrhoea [ Time Frame: 28 days post last antibiotic dose ]	positive	participants	0	not superior		https://pubmed.ncbi.nlm.nih.gov/23618760/	NCT00973908	Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2|phase3	https://ClinicalTrials.gov/show/NCT00973908			112.0	1.0
NCT01295918-1	sustained	100000000	700000000	100000000	cfu	qd	7	7 days + duration of antibiotics	probiotic	probioticsupplementcontaining1x108cfulactobacillusreuteridsm17938intheformofonechewabletabletonceperda	no	49	prophylactic	To assess if the probiotic L. reuteri is effective in preventing AAD in children [ Time Frame: 2 years ]	positive	participants	48	not superior	The incidence of diarrhoea (defined as at least 3 loose or watery stools per day in a 48-hour period that occurred during or up to 21 days after cessation of antibiotic treatment) was unexpectedly low in both groups - L. reuteri (n=1) versus placebo (n=1): 2,04 vs. 2,1 per 100 (p>0,05, risk ratio 1,02, 95% CI 0,7-1,4).	http://www.journal-imab-bg.org/issues-2015/issue4/vol21issue4p895-900.html	NCT01295918	Probiotic Lactobacillus Reuteri to Prevent Antibiotic-associated Diarrhea and Clostridium Difficile-related Infections in Hospitalized Children	all	child,adult	3 Years to 18 Years Â (Child, Adult)	phase3	https://ClinicalTrials.gov/show/NCT01295918		Lactobacillus reuteri, LMG P-27481	48.0	0.9795918367346939
NCT02589847-1	acute							given as quantity of enema	probiotic	rbx2660	no	142	therapeutic	Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks	positive	participants	112			x	NCT02589847	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02589847			112.0	0.7887323943661971
NCT02589847-3	sustained							given as quantity of enema	probiotic	rbx2660	no	142	therapeutic	Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks	positive	participants	112			x	NCT02589847	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02589847			112.0	0.7887323943661971
NCT02299570-1	sustained			2	enema			separated by 7 days	probiotic	rbx2660	yes	45	therapeutic	The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).	positive	participants	25			x	NCT02299570	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02299570			25.0	0.5555555555555556
NCT02299570-3	sustained			1	enema				probiotic	rbx2660	yes	44	therapeutic	The primary endpoint is to evaluate treatment success, defined as the absence of CDAD without the need for retreatment with C. difficile anti-infective therapy or fecal transplant (FT) at 56 days after administration of the last assigned study enema, of Group A (two enemas of RBX2660) vs. Group B (two enemas of placebo).	positive	participants	25			x	NCT02299570	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02299570			25.0	0.5681818181818182
NCT01925417-1	sustained								probiotic	rbx2660	no	31	therapeutic	Number of participants who were determined to be free of CDAD at Day 56 after receiving their last dose of RBX2660.	positive	participants	27			x	NCT01925417	Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01925417			27.0	0.8709677419354839
NCT02981316-2	sustained	8	32	4	capsules	bid	4		probiotic	rbx7455	yes	10	therapeutic	absence of rCDI at 8 weeks following completion of the final treatment	positive	participants	9			https://pubmed.ncbi.nlm.nih.gov/32966574/	NCT02981316	Treatment of Recurrent Clostridium Difficile Infection With RBX7455	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT02981316			9.0	0.9
NCT02981316-3	sustained	8	16	4	capsules	bid	2		probiotic	rbx7455	yes	10	therapeutic	absence of rCDI at 8 weeks following completion of the final treatment	positive	participants	8			https://pubmed.ncbi.nlm.nih.gov/32966574/	NCT02981316	Treatment of Recurrent Clostridium Difficile Infection With RBX7455	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT02981316			8.0	0.8
NCT02981316-4	sustained	4	8	2	capsules	bid	2		probiotic	rbx7455	yes	10	therapeutic	absence of rCDI at 8 weeks following completion of the final treatment	positive	participants	10			https://pubmed.ncbi.nlm.nih.gov/32966574/	NCT02981316	Treatment of Recurrent Clostridium Difficile Infection With RBX7455	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase1	https://ClinicalTrials.gov/show/NCT02981316			10.0	1.0
NCT02092935-1	acute	400	4000	200	mg	bid	10		antibiotic	ridinilazole	no	36	therapeutic	Clinical response at test of cure	positive	participants	28			https://pubmed.ncbi.nlm.nih.gov/28461207/	NCT02092935	A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02092935	SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969		28.0	0.7777777777777778
NCT02092935-3	sustained	400	4000	200	mg	bid	10		antibiotic	ridinilazole	no	28	therapeutic	Sustained clinical response	positive	participants	24	superior	wald	https://pubmed.ncbi.nlm.nih.gov/28461207/	NCT02092935	A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02092935	SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969		24.0	0.8571428571428571
NCT02784002-2	sustained	400	4000	200	mg	bid	10		antibiotic	ridinilazole	no	14	therapeutic	Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ]	positive	participants	7	equivalence	estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7	https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841	NCT02784002	A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02784002	SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole];SMT19969		7.0	0.5
NCT01670149-1	sustained	1200	25200	400	mg	tid	14	followed by 200mg TID for 14 days	antibiotic	rifaximin	no	69	prophylactic	Difference in % relapse between Rifaximin and placebo at 12 weeks [ Time Frame: 12 weeks ]	positive	participants	11	superior	a difference between groups of −13.7% (95% CI −28.1% to 0.7%, p=0.06). The risk ratio was 0.54 (95% CI 0.28 to 1.05, p=0.07	https://gut.bmj.com/content/66/Suppl_2/A150.1	NCT01670149	Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01670149	rifaximin		58.0	0.8405797101449275
NCT00269399-1	acute	1200	12000	400	mg	tid	10	400 mg TID	antibiotic	rifaximin	no	117	therapeutic	Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]	positive	participants	67			x	NCT00269399	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00269399	rifaximin		67.0	0.5726495726495726
NCT00269399-3	sustained	1200	12000	400	mg	tid	10	400 mg TID	antibiotic	rifaximin	no	67	therapeutic	Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]	positive	participants	61			x	NCT00269399	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00269399	rifaximin		61.0	0.9104477611940298
NCT02437487-1	acute			1	108sporq				probiotic	ser-109	no	59	therapeutic	Number of Subjects With CDI Recurrence (8 weeks after)	positive	participants	26	superior	relative risk, 2-sided 95% CI	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059	NCT02437487	SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02437487			33.0	0.559322033898305
NCT02437487-3	sustained			1	108sporq				probiotic	ser-109	no	59	therapeutic	Number of Subjects With CDI Recurrence (8 weeks after)	positive	participants	26	superior	relative risk, 2-sided 95% CI	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa387/5817059	NCT02437487	SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02437487			33.0	0.559322033898305
NCT02148601-2	sustained								antibiotic	standardantibiotictherapy	no	19	therapeutic	Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ]	positive	participants	5			https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144	NCT02148601	Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection	all	adult,olderadult	18 Years to 95 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02148601		vancomycin;vancomycin + metronidazole;metronidazole	5.0	0.2631578947368421
NCT02589847-2	acute								antibiotic	standardofcareantibiotics	no	75	therapeutic	Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks	positive	participants	23			x	NCT02589847	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02589847		vancomycin;vancomycin + metronidazole;metronidazole	23.0	0.30666666666666664
NCT02589847-4	sustained								antibiotic	standardofcareantibiotics	no	75	therapeutic	Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks	positive	participants	23			x	NCT02589847	Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02589847		vancomycin;vancomycin + metronidazole;metronidazole	23.0	0.30666666666666664
NCT01597505-1	acute	500	5000	250	mg	bid	10		antibiotic	surotomycin	no	290	therapeutic	Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)	positive	percentageofparticipants	79.0 (73.9 to 83.2)	Non-Inferiority	The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.	x	NCT01597505	Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01597505	CB-183,315;surotomycin		229.1	0.7896551724137931
NCT01597505-3	sustained	500	5000	250	mg	bid	10		antibiotic	surotomycin	no	290	therapeutic	Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study	positive	percentageofparticipants	60.6 (55.0 to 66.0)	not superior	The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.	x	NCT01597505	Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01597505	CB-183,315;surotomycin		175.74	0.603448275862069
NCT01598311-1	acute	500	5000	250	mg	bid	10		antibiotic	surotomycin	no	285	therapeutic	Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)	positive	percentageofparticipants	83.4 (78.7 to 87.2)	Non-Inferiority	Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.	Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.	NCT01598311	A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)	all	adult,olderadult	18 Years to 89 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01598311	CB-183,315;surotomycin		237.69	0.8315789473684211
NCT01598311-3	sustained	500	5000	250	mg	bid	10		antibiotic	surotomycin	no	285	therapeutic	Adjusted Percentage of Participants With Sustained Clinical Response at End of Study	positive	percentageofparticipants	63.3 (57.7 to 68.7)	not superior	Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.	x	NCT01598311	A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)	all	adult,olderadult	18 Years to 89 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01598311	CB-183,315;surotomycin		180.405	0.631578947368421
NCT02563106-1	sustained	600	4800	150	mg	qid	8	3 days + at least 5 days of antibiotics duration	other	syn-004	no	206	prophylactic	Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up.	positive	participants	2	relative risk reduction	(risk reduction 2·4%, 95% CI -0·6 to 5·9; one-sided p=0·045)	x	NCT02563106	A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI	all	adult,olderadult	50 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02563106			204.0	0.9902912621359223
NCT00196794-1	acute	9	135	3	g	tid	14	3g + 9g loading dose	antibiotic	tolevamerpotassium-sodium(gt267-004)	no	268	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	41.8			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	GT160-246		112.024	0.417910447761194
NCT00196794-7	sustained	9	135	3	g	tid	14	3g + 9g loading dose	antibiotic	tolevamerpotassium-sodium(gt267-004)	no	105	therapeutic	Recurrence rate	positive	percentageofparticipants	5.7			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	GT160-246		99.015	0.9428571428571428
NCT00106509-1	acute	9	135	3	g	tid	14	3g + 9g loading dose	antibiotic	tolevamerpotassium-sodium(gt267-004)	no	266	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	46.6			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	GT160-246		123.956	0.462406015037594
NCT00106509-7	sustained	9	135	3	g	tid	14	3g + 9g loading dose	antibiotic	tolevamerpotassium-sodium(gt267-004)	no	117	therapeutic	Recurrence rate	positive	percentageofparticipants	3.4			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	GT160-246		113.022	0.9658119658119658
NCT02423967-1	sustained								fmt	transplantusesfreshfamilialstool	no	2	therapeutic	Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant [ Time Frame: 4 weeks ]	positive	participants	1			https://journals.lww.com/jpgn/Fulltext/2016/10002/World_Congress_of_Pediatric_Gastroenterology,.1.aspx	NCT02423967	Fresh Versus Frozen Stool for Fecal Transplant in Children	all	child,adult	1 Year to 18 Years Â (Child, Adult)	phase1	https://ClinicalTrials.gov/show/NCT02423967		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	1.0	0.5
NCT02423967-2	sustained								fmt	transplantusesfrozenanonymousstool	no	6	therapeutic	Clostridium difficile (CD) Eradication; percentage of patients with negative CD toxin in stool following Fecal Microbiota Transplant [ Time Frame: 4 weeks ]	positive	participants	6	non-inferior		https://journals.lww.com/jpgn/Fulltext/2016/10002/World_Congress_of_Pediatric_Gastroenterology,.1.aspx	NCT02423967	Fresh Versus Frozen Stool for Fecal Transplant in Children	all	child,adult	1 Year to 18 Years Â (Child, Adult)	phase1	https://ClinicalTrials.gov/show/NCT02423967		FMT-FD;FMT-G10;FMT-G80;caecal contents;FMT;cecal homogenates	6.0	1.0
NCT01983683-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	301	therapeutic	Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population	positive	percentageofparticipants	85.7 (81.3 to 89.2) 		Wilson's score method	x	NCT01983683	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01983683	vancomycin		257.957	0.8538205980066446
NCT01983683-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	301	therapeutic	"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT)."	positive	percentageofparticipants	61.8 (56.2 to 67.1)	Inferiority	Wilson's score method	x	NCT01983683	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01983683	vancomycin		186.018	0.6179401993355482
NCT01987895-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	318	therapeutic	Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population	positive	percentageofparticipants	85.2 (80.9 to 88.7) 		Wilson's score method	x	NCT01987895	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01987895	vancomycin		270.93600000000004	0.8490566037735849
NCT01987895-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	318	therapeutic	"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT)."	positive	percentageofparticipants	62.3 (56.8 to 67.4)	Inferiority	Wilson's score method	x	NCT01987895	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01987895	vancomycin		198.11399999999998	0.6226415094339622
NCT02254967-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	179	therapeutic	clinical reponse 2 days after end of treatment	positive	participants	147		Cochran-Mantel-Haenszel	https://doi.org/10.1016/s1473-3099(17)30751-x	NCT02254967	A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population	all	adult,olderadult	60 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02254967	vancomycin		147.0	0.8212290502793296
NCT02254967-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	179	therapeutic	sustained clinical cure 30 days after end of treatment	positive	participants	106	Superiority	Cochran-Mantel-Haenszel	https://doi.org/10.1016/s1473-3099(17)30751-x	NCT02254967	A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population	all	adult,olderadult	60 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT02254967	vancomycin		106.0	0.5921787709497207
NCT01597505-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	280	therapeutic	Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT)	positive	percentageofparticipants	83.6 (78.8 to 87.4)		The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.	x	NCT01597505	Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01597505	vancomycin		234.08	0.8357142857142857
NCT01597505-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	280	therapeutic	Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study	positive	percentageofparticipants	61.4 (55.9 to 66.8)  		The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.	x	NCT01597505	Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01597505	vancomycin		171.92	0.6107142857142858
NCT01598311-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	292	therapeutic	Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT)	positive	percentageofparticipants	82.1 (77.2 to 85.9)		Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.	x	NCT01598311	A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)	all	adult,olderadult	18 Years to 89 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01598311	vancomycin		239.73199999999997	0.8184931506849316
NCT01598311-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	292	therapeutic	Adjusted Percentage of Participants With Sustained Clinical Response at End of Study	positive	percentageofparticipants	59.0 (53.4 to 64.5)		Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.	x	NCT01598311	A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)	all	adult,olderadult	18 Years to 89 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT01598311	vancomycin		172.28	0.589041095890411
NCT02179658-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	108	therapeutic	Clinical cure at end of treatment	positive	participants	95			https://pubmed.ncbi.nlm.nih.gov/29934056/	NCT02179658	A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	adult,olderadult	20 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02179658	vancomycin		95.0	0.8796296296296297
NCT02179658-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	108	therapeutic	Global cure at end of treatment	positive	participants	71		with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%	https://pubmed.ncbi.nlm.nih.gov/29934056/	NCT02179658	A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	adult,olderadult	20 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02179658	vancomycin		71.0	0.6574074074074074
NCT02743234-5	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	16	therapeutic	Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ]	positive	participants	3			https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234	vancomycin		3.0	0.1875
NCT02743234-11	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	16	therapeutic	initially cured, then relapsed	positive	participants	11			https://doi.org/10.1053/j.gastro.2018.12.019	NCT02743234	Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection	all	adult,olderadult	18 Years to 99 Years Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT02743234	vancomycin		5.0	0.3125
NCT01222702-10	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	yes	22	therapeutic	Modified clinical cure rate	positive	participants	19			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	vancomycin		19.0	0.8636363636363636
NCT01222702-22	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	yes	22	therapeutic	Modified sustained clinical response rate	positive	participants	12			https://aac.asm.org/content/59/10/6266	NCT01222702	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01222702	vancomycin		12.0	0.5454545454545454
NCT02218372-2	acute	500	5000	125	mg	qid	10	staggered age dependent dose, recorded >6 years dosage	antibiotic	vancomycin	no	44	therapeutic	Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days	positive	percentageofparticipants	70.5 (54.6 to 83.2)		Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.	x	NCT02218372	A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child	up to 17 Years Â (Child)	phase3	https://ClinicalTrials.gov/show/NCT02218372	vancomycin		31.02	0.7045454545454546
NCT02218372-4	sustained	500	5000	125	mg	qid	10	staggered age dependent dose, recorded >6 years dosage	antibiotic	vancomycin	no	31	therapeutic	Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days	positive	percentageofparticipants	77.4 (58.9 to 90.4)		Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.	x	NCT02218372	A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)	all	child	up to 17 Years Â (Child)	phase3	https://ClinicalTrials.gov/show/NCT02218372	vancomycin		23.994	0.7419354838709677
NCT00468728-1	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	256	therapeutic	Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ]	positive	percentageofparticipants	86.7 (82.0 to 90.4)		H0: C(OPT-80) - C(VAN) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.	x	NCT00468728	PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00468728	vancomycin		221.952	0.86328125
NCT00468728-3	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	222	therapeutic	Recurrence [ Time Frame: Study days 11-40 ]	positive	percentageofparticipants	22		Chi-squared	x	NCT00468728	PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00468728	vancomycin		173.16	0.7792792792792793
NCT00314951-1	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	307	therapeutic	Cure Rate at End of Therapy [ Time Frame: Study day 10 (+/- 2 days) ]	positive	percentageofparticipants	85.7 (81.3 to 89.2)		H0: C(fidaxomicin) - C(Vancomycin) <= -10% Power calculation is based on cure rate of 85% in both treatment groups, non-inferiority margin of 10%, 2.5% (1-sided) type I error rate with approximately 90% power gives a total of 530 subjects.	x	NCT00314951	Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00314951	vancomycin		263.099	0.8566775244299675
NCT00314951-3	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	263	therapeutic	Recurrence [ Time Frame: Study days 11-40 ]	positive	percentageofparticipants	25.1		Chi-squared	x	NCT00314951	Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)	all	child,adult,olderadult	16 Years and older Â (Child, Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00314951	vancomycin		196.987	0.7452471482889734
NCT00269399-2	acute	500	5000	125	mg	qid	10	125 mg QID	antibiotic	vancomycin	no	115	therapeutic	Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]	positive	participants	73			x	NCT00269399	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00269399	vancomycin		73.0	0.6347826086956522
NCT00269399-4	sustained	500	5000	125	mg	qid	10	125 mg QID	antibiotic	vancomycin	no	73	therapeutic	Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]	positive	participants	63			x	NCT00269399	A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00269399	vancomycin		63.0	0.863013698630137
NCT00196794-5	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	125	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	80.8			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	vancomycin		101.0	0.808
NCT00196794-11	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	102	therapeutic	Recurrence rate	positive	percentageofparticipants	17.6			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00196794	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00196794	vancomycin		84.048	0.8235294117647058
NCT00106509-5	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	134	therapeutic	Resolution of diarrhea	positive	percentageofparticipants	81.3			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	vancomycin		108.942	0.8059701492537313
NCT00106509-11	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	107	therapeutic	Recurrence rate	positive	percentageofparticipants	23.4			https://pubmed.ncbi.nlm.nih.gov/24799326/	NCT00106509	A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase3	https://ClinicalTrials.gov/show/NCT00106509	vancomycin		81.962	0.7570093457943925
NCT02092935-2	acute	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	33	therapeutic	Clinical response at test of cure	positive	participants	23			https://pubmed.ncbi.nlm.nih.gov/28461207/	NCT02092935	A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02092935	vancomycin		23.0	0.696969696969697
NCT02092935-4	sustained	500	5000	125	mg	qid	10		antibiotic	vancomycin	no	23	therapeutic	Sustained clinical response	positive	participants	14	inferior	wald	https://pubmed.ncbi.nlm.nih.gov/28461207/	NCT02092935	A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)	all	adult,olderadult	18 Years to 90 Years Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT02092935	vancomycin		14.0	0.6086956521739131
NCT01818141-2	acute	500	5000	125	mg	qid	10	125 mg QID for 10 days	antibiotic	vancomycin125mgbymouthevery6hoursfor10days	no	9	therapeutic	C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool	positive	participants	6			x	NCT01818141	Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01818141	vancomycin		6.0	0.6666666666666666
NCT01818141-4	acute	500	5000	125	mg	qid	10	125 mg QID for 10 days	antibiotic	vancomycin125mgbymouthevery6hoursfor10days	no	5	therapeutic	C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool	positive	participants	5			x	NCT01818141	Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase4	https://ClinicalTrials.gov/show/NCT01818141	vancomycin		5.0	1.0
NCT01259726-4	sustained	10000	70000	10000	spores	qd	7		probiotic	vp20621	yes	41	therapeutic	Number of Participants With Clostridium Difficile Infection (CDI) Recurrence	positive	participants	6	superior	Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.	x	NCT01259726	Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01259726	M3, a NTCD strain	Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain	35.0	0.8536585365853658
NCT01259726-7	sustained	10000000	70000000	10000000	spores	qd	7		probiotic	vp20621	yes	43	therapeutic	Number of Participants With Clostridium Difficile Infection (CDI) Recurrence	positive	participants	2	superior	Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.	x	NCT01259726	Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01259726	M3, a NTCD strain	Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain	41.0	0.9534883720930233
NCT01259726-10	sustained	10000000	140000000	10000000	spores	qd	14		probiotic	vp20621	yes	41	therapeutic	Number of Participants With Clostridium Difficile Infection (CDI) Recurrence	positive	participants	6	superior	Treatment comparison with placebo using two-sided Chi-Square test at significance level p=0.05.	x	NCT01259726	Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection	all	adult,olderadult	18 Years and older Â (Adult, Older Adult)	phase2	https://ClinicalTrials.gov/show/NCT01259726	M3, a NTCD strain	Z31, a NTCD strain;NTCD-035;PCD130 + 027;PCD182 + 027;Strain 630;Clostridium difficile CD37;T7, a NTCD strain	35.0	0.8536585365853658
